Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130019 | 0.94 | TRPV1 (0.65) | ALDH1A1KDM4EGAAHPGDSMN1; SMN2 | |
| SCHEMBL428336 | 0.84 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL429451 | 0.84 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL430783 | 0.81 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL431156 | 0.81 | TRPV1 (0.52) | ALDH1A1KDM4EGAAHPGDSMN1; SMN2 | |
| SCHEMBL701314 | 0.79 | TAS1R3 (1.00) | ALDH1A1KDM4EGAAHPGDSMN1; SMN2 | |
| SCHEMBL703637 | 0.79 | TAS1R3 (1.00) | ALDH1A1KDM4EGAAHPGDSMN1; SMN2 | |
| SCHEMBL2317277 | 0.79 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL2359763 | 0.79 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL430387 | 0.78 | TRPV1 (0.60) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045546-A1 | Tetradydro-Naphthalene And Urea Derivatives | NMUR1, GPR17, NMUR2 | ALDH1A1 477/4885KDM4E 4837/4885GAA 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.